We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Places Hold on Gilead’s Injectable HIV Drug Over Possible Glass Contaminants
FDA Places Hold on Gilead’s Injectable HIV Drug Over Possible Glass Contaminants
The FDA has put a clinical hold on Gilead Sciences’ injectable HIV drug lenacapavir because of the risk of glass particles from the vials getting into the medication.